Braxia Scientific Corp. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Toronto, ontario--(newsfile corp. - february 29, 2024) - braxia scientific corp. (cse: brax) (otc pink: braxf) (fse: 4960), ("braxia scientific", or the "company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and nine months ended december 31, 2023. complete financial statements along with related management discussion and analysis can be found in the system for electronic document analysis and retrieval (sedar+), the electronic filing system for the disclosure documents of issuers across canada, at www...

Toronto, ontario--(newsfile corp. - january 15, 2024) - braxia scientific corp. (cse: brax) (otc pink: braxf) (fse: 4960), ("braxia scientific", or the "company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the mandatory conversion of $2,935,714 in convertible debentures, which matured on december 31, 2023, into 19,571,411 common shares at a conversion price of $0.15 per common share. about braxia scientific corp. braxia scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Toronto, ontario--(newsfile corp. - november 30, 2023) - braxia scientific corp. (cse: brax) (otc pink: braxf) (fse: 4960) ("braxia scientific", or the "company"), a medical research company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and six months ended september 30, 2023. complete financial statements along with related management discussion and analysis can be found in the system for electronic document analysis and retrieval (sedar+), the electronic filing system for the disclosure documents of issuers across canada, at www...

Toronto, ontario--(newsfile corp. - august 30, 2023) - braxia scientific corp. (cse: brax) (otc pink: braxf) (fse: 4960) ("braxia scientific", or the "company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months ended june 30, 2023. complete financial statements along with related management discussion and analysis can be found in the system for electronic document analysis and retrieval (sedar+), the electronic filing system for the disclosure documents of issuers across canada, at www...

Braxia health ketamine treatments up 26% yoy in 2023 and revenue up 27% yoy company completes dosing of final participant in phase 2, multi-dose psilocybin trial, results expected to be published prior to end of 2023 company reviewing financing options, strategic partnerships and further cost reductions and organizational changes as required toronto, ontario--(newsfile corp. - july 31, 2023) - braxia scientific corp. (cse: brax) (otc pink: braxf) (fse: 4960) ("braxia scientific", or the "company"), a medical research and telemedicine company with clinics providing innovative ketamine and psilocybin treatments for depression and related disorders, today announced the filing of its financial statements and management discussion and analysis for the three months and twelve months ended march 31, 2023...

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has reported a significant increase in treatment volumes across its clinics, which rose by 26.2% in fiscal 2023 to 3,516, compared to 2,785 treatments in the previous year. The company said its growth has been driven by increased demand across all five of its clinics.

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) announced that Irwin Naturals Inc has terminated the non-binding amended and restated letter of intent (LOI) for a business combination between Irwin and Braxia, which the company called “disappointing”.   The medical research and telemedicine firm, however, said it remains committed to evaluating a number of potential strategic opportunities to create shareholder value in the mental health industry, which continues to evolve and consolidate.

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has reported third-quarter results that show a sharp rise in revenue as the company increased its in-clinic ketamine treatments and continued to expand its US telemedicine platform, KetaMD. The medical research and telemedicine company also updated investors on its proposed acquisition by Irwin Naturals Inc. (CSE:IWIN) after the two companies entered into a non-binding Letter of Intent (LOI) in January.

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) said it has closed the first tranche of its previously announced non-brokered offering resulting in the issuance of 13,658,524 units of the company at a price of 5.5 cents per unit for aggregate proceeds of $751,218.83. The company said it intends to use the net proceeds of the LIFE offering and the concurrent placement to support the rollout of its telemedicine platform in the United States, for clinic expansion in Canada and to continue intellectual property development, and the company expects to use the net proceeds of the concurrent placement for working capital and general corporate purposes.

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced an offering of up to 27,272,727 units of the company at a price of $0.055 each for aggregate proceeds of up to $1.5 million pursuant to the listed issuer financing exemption (LIFE) and a concurrent private placement of up to 7,272,727 units for aggregate gross proceeds of up to $400,000. The net proceeds of the LIFE offering will be used to support the rollout of the company's telemedicine platform in the United States, for clinic expansion in Canada, and to continue intellectual property development, Braxia said.

Irwin Naturals Inc. (CSE:IWIN) said it has entered into a non-binding amended and restated Letter of Intent (LOI) for a business combination with Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) in a move it said will create a new market leader in North American mental health. The company noted that Braxia Scientific is a medical research and telemedicine company with clinics that provide innovative ketamine treatments for persons with depression and related disorders.

Irwin Naturals Inc. (CSE:IWIN) and Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) have signed a Letter of Intent (LOI) entering into a partnership to launch Clinical Research Services across Irwin's growing US-based network of clinics, Emergence. Under the LOI, Irwin will invest up to $2 million over the next 12 months to launch initial research services beginning with at least five clinics in Florida.

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced an increase in revenues for its second quarter and the first half ended September 30, 2022, with in-clinic treatment rising by 34.5% as it continues to build on its core strengths and priorities.  The company also said it also evaluating strategic capital market opportunities to create shareholder value.

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) has announced the expansion of its ketamine therapy program to help Floridians cope with mental health, including those affected by Hurricane Ian. Braxia's wholly-owned KetaMD subsidiary provides at-home ketamine treatments for Florida residents suffering from depression and related mental health conditions through telemedicine and a mobile app.

Braxia Scientific Corp. (CSE:BRAX, OTC:BRAXF) said it has successfully launched KetaMD in the US state of Florida, adding new patients and completing initial ketamine treatments. Eligible patients, as determined by one of KetaMD's licensed Florida healthcare practitioners, received medically supervised treatments, guided virtually by registered nurses with mental health expertise, while in the comfort of their homes, according to Braxia.